← Eichor
Condition: Newly Diagnosed Glioblastoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Newly Diagnosed Glioblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT05083754Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Phase 2 · 1 location(s) · Duke University · NCT06816927HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Phase 1/Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT03603405Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared
Phase 3 · 1 location(s) · Northwell Health · NCT05271240Imaging Acetadote Metabolism in Glioblastoma
EARLY_Phase 1 · 1 location(s) · University of Texas Southwestern Medical Center · NCT07387666ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combinatio
Phase 2 · 5 location(s) · Cedars-Sinai Medical Center · NCT05708352Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Phase 2 · 1 location(s) · Northwestern University · NCT05864534Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-
NA · 6 location(s) · BioTex, Inc. · NCT06533163Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Di
Phase 2 · 11 location(s) · Alpheus Medical, Inc. · NCT07225621LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
NA · 5 location(s) · University of Maryland, Baltimore · NCT04699773Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
EARLY_Phase 1 · 1 location(s) · Stony Brook University · NCT05423210Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Di
Phase 1 · 20 location(s) · Children's Oncology Group · NCT06894979A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase 1/Phase 2 · 3 location(s) · Novelwise Pharmaceutical Corporation · NCT07569042Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Phase 2 · 22 location(s) · Black Diamond Therapeutics, Inc. · NCT07326566NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Phase 1/Phase 2 · 4 location(s) · Novelwise Pharmaceutical Corporation · NCT06012695D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Phase 1/Phase 2 · 1 location(s) · Darell Bigner · NCT05734560BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
EARLY_Phase 1 · 1 location(s) · Nader Sanai · NCT07485049Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
NA · 2 location(s) · Medical University of Warsaw · NCT07488754Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Phase 3 · 20 location(s) · Vastra Gotaland Region · NCT06419946Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Phase 1/Phase 2 · 1 location(s) · Northwell Health · NCT02861898Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
EARLY_Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06831526A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
Phase 1 · 1 location(s) · CHA University · NCT07143812Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progressio
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07670026Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type
NA · 16 location(s) · Istituto Oncologico Veneto IRCCS · NCT06964815DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Phase 1/Phase 2 · 5 location(s) · University of California, San Francisco · NCT06504381Anterior Temporal Lobectomy in Temporal Glioblastoma
Phase 3 · 1 location(s) · University Hospital, Bonn · NCT07021339
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.